Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Filed Aug 3, 2026 · 10-Q · 34 days after period end · 0001628280-26-051895
| Metric | Q2 2026 | Q2 2025 | Q2 2024 |
|---|---|---|---|
| Revenue | $343.00M | $302.00M | $299.00M |
| Net Income | $122.00M | $18.00M | -$97.00M |
| EPS Diluted | $0.98 | $0.14 | -$0.72 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end
